VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 27,969 shares, a decline of 69.3% from the March 31st total of 91,217 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily volume of 64,190 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is owned by institutional investors and hedge funds.

VivoSim Labs Trading Down 1.4%

Shares of VIVS stock opened at $1.46 on Friday. The stock has a 50 day simple moving average of $1.74 and a 200-day simple moving average of $2.06. The company has a market cap of $3.81 million, a price-to-earnings ratio of -0.46 and a beta of 1.43. VivoSim Labs has a 12-month low of $1.25 and a 12-month high of $5.30.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings data on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. The business had revenue of $0.03 million during the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, VivoSim Labs currently has an average rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.